Key Takeaways for argenx Stock as of August 2026
- Trial Win: ALKIVIA, the Phase 3 study of VYVGART Hytrulo in autoimmune myositis, hit its primary endpoint at week 52 with a p-value of 0.0011, sending argenx stock up 17% on Monday, August 17 to close near $990.
- Ratings Reset: The Street’s current split sits at 4 buys, 1 outperform, 1 hold and 1 underperform, a sharp pullback from the 10 buys and 3 outperforms analysts carried into the readout.
- Target Gap Closed: The mean price target of $888 now sits below Monday’s $990 close, a reversal from a year of the target running ahead of the stock.
- Model Upside: TIKR’s mid-case model still puts a $2,157 target price on argenx stock, implying 118% total return and a 20% annualized rate through 2030.
Why argenx Stock Jumped 17% on Monday’s Myositis Trial Win
argenx (ARGX) stock jumped 17% on Monday, August 17, adding roughly $145 to close near $990 after the company announced positive topline results from its Phase 3 ALKIVIA trial. The study tested VYVGART Hytrulo, the subcutaneous version of argenx’s antibody fragment efgartigimod, in adults with autoimmune myositis. It worked. And it worked at a level analysts hadn’t fully priced in.
The trial met its primary endpoint in the combined population of two myositis subtypes, immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM), with a p-value of 0.0011. Patients on efgartigimod showed a 15.4-point greater improvement in Total Improvement Score (TIS) at week 52 than those on placebo, a composite measure spanning muscle strength, physical function and disease activity. The benefit showed up as early as week 4 and held through the full year, even as patients tapered off corticosteroids starting at week 16.
IMNM is the more urgent story. No approved therapy exists for the roughly 20,000 U.S. patients living with it, a disease that can move from diagnosis to wheelchair in months. In that group, the drug’s benefit was strong enough that chance alone can’t explain it: patients on efgartigimod improved nearly 15 points more than those on placebo on the trial’s main symptom scale, a big enough margin to count as a real, provable win. DM patients improved by almost the identical amount, about 14 points more than placebo. But because fewer DM patients were enrolled in the trial, that result narrowly missed the bar statisticians use to call a result “proven,” even though the drug worked just as well in both groups. The shortfall came down to trial size, not a weaker drug.
CEO Karen Massey didn’t hedge on what comes next. “In IMNM, where we have breakthrough therapy designation, we intend to move rapidly towards submission,” she told analysts on the call. “In DM, we have strong conviction in these data and what they mean for patients, and we’ll engage with the regulators on a path forward.” That’s a company treating a topline readout as a launch countdown, not a data point.
William Blair’s Matt Phipps modeled peak sales near $3 billion for the IMNM indication alone, with commercialization targeted for late 2027, and another $1.7 billion in DM despite tougher competition there. Combined, the two subtypes represent close to 60,000 U.S. patients, a population Massey compared directly to myasthenia gravis, the indication that turned VYVGART into a blockbuster in the first place.
The move mattered because it erased a binary risk that had hung over argenx stock for months. A failed readout would have stalled the rheumatology expansion before it started. Instead, the data gave the company its sixth positive Phase 3 result for the FcRn platform and a credible route into a specialty where it has never sold a drug.
Street Analysts Target argenx Stock After the Myositis Data
Coming into Monday’s readout, the Street’s ratings on argenx stock had already thinned out considerably. The current split shows 4 buys, 1 outperform, 1 hold and 1 underperform, against a mean target of $888. That target sat 4% above the $855 price close carried in the table’s most recent column, a gap that Monday’s 17% jump erased entirely.
That compression didn’t happen overnight. A year ago, the mean target of $646 sat 38% above a $470 stock. Every quarter since, the target climbed alongside the price, from $720 to $820 to $845 to $874, but the cushion between the two kept shrinking, down to just 4% heading into August. Analysts were raising numbers, but the stock was closing the gap faster than they could write new notes.
The ratings count tells its own story. Ten analysts carried buy ratings on argenx stock as recently as June 30, alongside 3 outperforms and 2 holds. By the August snapshot, buys had fallen to 4 and an underperform rating had appeared for the first time in the table’s history.
Coverage often gets pulled or placed under review ahead of a binary clinical readout, and that’s what this looks like: analysts stepping back rather than making a call before ALKIVIA reported. Now that the data is in, the Street has room to move its targets higher, and the ratings reset from before the print gives a clean baseline for how much conviction returns.
TIKR Values argenx Stock at $2,157, Pricing In the Myositis Launch
TIKR’s mid-case model values argenx stock at $2,157 by December 2030, implying 118% total return from the current price of $990, or 20% annualized over 4.4 years.
That return profile puts argenx stock well ahead of typical large-cap biotech returns, where mid-teens annualized gains are the exception rather than the rule. The model isn’t leaning on a single catalyst to get there; it’s built on a revenue growth path in the high teens through 2035 alongside a net income margin recovering from negative territory today to roughly 41% at the mid case.
The ALKIVIA data give that path a new leg. IMNM adds a launch with no competing therapy and breakthrough designation already in hand, while DM opens a second front in a market where argenx has never had a foothold before.
Both readouts land on top of a VYVGART franchise that already generated $1.52 billion in revenue last quarter at a 59% gross margin, up from just under 50% two years ago, and the Street’s ratings reset ahead of the trial means upgrades, not downgrades, are the more likely next move.
Should You Invest in argenx SE?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up argenx SE stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track argenx SE alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ARGX stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
